CoChat

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials

Bikou, Alexia, Dermiki-Gkana, Foteini, Penteris, Michail, Constantinides, Theodoros K, Kontogiorgis, Christos · 2024 · Expert Opinion on Pharmacotherapy

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Semaglutide, a glucagon-like peptide-1 receptor agonist, is associated with significant weight loss, yet its impact on lean body mass remains insufficiently understood. This review investigates the effect of semaglutide on lean mass in the context of obesity management. METHODOLOGY: This study investigates through different databases (PubMed, Elsevier, and Google Scholar) from 2016 for randomized control trials (RCTs) or observational studies that assessed the use of semaglutide in overweight or obese patients, regardless of whether they have type 2 diabetes or not. The studies compared semaglutide to a placebo or alternative medications. RESULTS: Six studies with 1,541 overweight or obese adults were included, and significant weight reductions were observed primarily due to fat mass loss. While the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others. Noteworthy decreases in lean mass were particularly evident in larger trials, yet the proportion of lean mass relative to total body mass increased, suggesting a positive overall outcome. CONCLUSION: Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass, especially in trials with a larger number of patients.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2024.2343092

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 97

Metadata

Authors
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C.
Affiliations
  • Democritus University of Thrace (GR)
  • Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
Corresponding author
Kontogiorgis, Christos
Venue
Expert Opinion on Pharmacotherapy
Published
2024-03-23
Volume
25
Issue
5
Pages
611-619
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W4394874190
Cited by
97
References
51
Citations by year
2026: 47 · 2025: 35 · 2024: 14
FWCI
6.01
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
semaglutide, lean body mass, fat loss, weight loss, obesity, overweight, GLP-1 receptor agonists, type 2 diabetes, body composition
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. https://app.cochat.ai/papers/10.1080/14656566.2024.2343092
The paper
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2024.2343092

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.